Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00003081
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00003270
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003146
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
- Conditions
- Interventions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 51
- Registration Number
- NCT00002768
- Locations
- 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
- Conditions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Mesoblast International Sàrl
- Registration Number
- NCT00081055
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005948
- Locations
- 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT00002592
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT00002789
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 240
- Registration Number
- NCT00005866
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸CCOP - Virginia Mason Research Center, Seattle, Washington, United States
🇺🇸St. Louis University Health Sciences Center, Saint Louis, Missouri, United States
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
- Conditions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00006126
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.